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Abstract
Background: The oncologic safety of blunt tumor enucleation (TE) of renal cell carci-
noma (RCC) depends on the presence of a continuous pseudocapsule (PS) around
the tumor and on the possibility of obtaining negative surgical margins (SMs).
Objective: To investigate the PS and SMs after TE to define the real need to take a rim
of healthy parenchyma around the tumor to avoid the risk of positive SMs. The risk
of PS invasion related to other clinical and pathologic variables was also evaluated.
Design, setting, and participants: Between September 2006 and December 2007, data
were gathered prospectively from 187 consecutive patients who had kidney surgery.
Overall, 90 consecutive patients who had TE for RCC were eligible for the study. All
specimens were evaluated using an image analyzer by a dedicated uropathologist.
Intervention: TE was done by blunt dissection using the natural cleavage plane
between the tumor and the normal parenchyma.
Measurements: PS, SM, and routinely available clinical andpathologic variableswere
recorded.
Results and limitations: In 60 RCC tumors (67%) the PS was intact and free from
invasion (PS) while in 30 (33%) there were signs of penetration within its layers,
with or without invasion beyond it. Indeed, 26.6% had PS that had been penetrated
on the parenchymal side and 6.6% had penetration on the perirenal fat tissue side.
The odds of having PS penetration increased significantlywith an increase in clinical
tumor size. PS penetration was also significantly associated with pathologic tumor
dimensions and grade. In all cases the SMs were negative after TE. The present
patients, followed for >2 yr, will enable us to correlate the risk of local recurrence
with PS status.
* Corresponding author. Clinica Urologica I, Azienda Ospedaliera Careggi, Universita` di
Firenze, Villa Monna Tessa, Viale Pieraccini 18, 50139, Firenze, Italy. Tel. +39 055 417645;
Fax: +39 055 4377755.
E-mail address: andreamine@libero.it (A. Minervini).0302-2838/$ – see back matter# 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi:10.1016/j.eururo.2008.07.038
Conclusions: The risk of PS penetration is associated with clinical and pathologic
tumor dimensions and grade. If there is PS invasion into normal parenchyma, the
presence of a thin layer of tissue allows for negative SM even if a TE is performed.
# 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Nephron-sparing surgery (NSS) has been widely
accepted since the early 1980s [1–2] as an elective
procedure for treating single sporadic renal tumors.
Several studies have shown this procedure to offer
equally effective local control and a similar disease-
specific survival rate compared to radical nephrec-
tomy (RN) for treating renal-cell carcinoma (RCC)
tumors of <4 cm in their greatest dimension [1–4].
Moreover, recent reports have shown that NSS
achieves local tumor control equivalent to RN also
for RCC of 4–7 cm [5,6].
The concern about local recurrence due to inade-
quate tumor excision and the reported risk of
pseudocapsule (PS) invasion on the parenchymal
side [7–11] led most surgeons to remove a minimal
rim of normal-appearing parenchyma around the
tumor, and at present this is considered to be the
technique of choice in patients undergoing NSS [1,2].
Nevertheless, in recent years there have been several
reports on the reduction of the thickness of the safety
margins that should be excised with the tumor to
avoid the risk of local recurrence. Others have
recently gone further, concluding that, if the tumor
is completely excised, the width of the resection
margin is irrelevant and not correlated with disease
progression, thus providing an intriguing insight into
the real need to excise an adequate rim of healthy
kidney tissue around the tumor [11–15].
The tumor enucleation (TE) technique, which
consists of excising the tumor by blunt dissection
without a visible rim of normal parenchyma, has
been reported in the treatment of benign-looking
tumors such as angiomyolipomas. But only a few
studies in the 1980s and early 1990s reported on the
use of this technique for treating small RCC tumors,
and they showed similar 5-yr survival rates to those
of partial nephrectomy [16–19]. Recently, other retro-
spective analyses confirmed that TE can be safely
used for treating pT1a–pT1b RCC tumors, and it is not
associated with any greater risk of local recurrence
than is partial nephrectomy [20–23]. Therefore, the
discrepancy between theoptimal oncologic results of
in vivo TE reported in several recent retrospective
analyses [20–23] and the pathologic concerns of
incomplete tumor excision based on data obtained
by studies after an ex vivo TE or tumor sections of RNspecimens remains an unsolved oncologic issue in
conservative kidney surgery [8,9–11].
The objective of this prospective study was to
investigate the existence, integrity, possible inva-
sion of peritumoral PS and surgical margin (SM)
status after NSS, performed as TE for the treatment
of RCC, with the aim of characterizing PS in RCC and
defining the real need to take a rim of healthy
parenchyma around the tumor to avoid the risk of a
positive SM.
2. Methods
Between September 2006 and December 2007, data were
gatheredprospectively from187 consecutive patientswhohad
kidney surgery. Overall, 104 (55.6%) had a conservative
treatment, TE, while 83 (44.4%) had RN. All but one NSS were
successful; in one case with imperative indications for a 4-cm
tumor, we decided to convert to RN for the intraoperative
detection of intrarenal vein thrombosis after TE. The patho-
logic evaluation in this case confirmed the presence of renal
vein thrombosis (pT3b). No patients had laparoscopic NSS.
Thedecision to proceedwith plannedNSSwas basedon the
patients’ preoperative imaging evaluation, medical history,
comorbidity, and age. None of the patients undergoing NSS
hadpreoperative or intraoperative suspicion of positive nodes.
All patients were free from distant metastases before surgery
(M0). The preoperative evaluation in all patients included
computed tomography (CT) of the abdomen, a chest x-ray, and
ultrasonography of the kidney, ureter, and bladder.
2.1. Surgical technique: tumor enucleation
In all cases, TEwas done according to our previously described
standard protocol, by blunt dissection and always using the
natural cleavage plane between the tumor and normal
parenchyma [20–22]. The kidney was directly approached
and completely separated from perirenal fat to exclude
subcapsular satellite lesions not detected by imaging. Intra-
operative ultrasonography was not used during this period.
After kidney capsule skeletonization, it was important to
visualize the limit between the healthy renal parenchyma and
the tumor, leaving the peritumoral fat in situ. The renal
pedicle was carefully isolated and usually controlled with
vascular clamps before TE. Renal hypothermia with slush was
not used during this period. The kidney capsule was then
sharply incised starting 1–2 mm away from the lesion toward
the PS, and when the PS was visually reached, the tumor was
enucleated by blunt dissection, with no visible rim of normal
parenchyma (Fig. 1). Biopsies of the surgical bed were not
taken during this period. The visible bleeding vessels and
Fig. 1 – Tumor enucleations (TEs).
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suture with 4-0 monofilament. Diathermy spray or argon-
beam coagulation of the surgical bed was not used during
this period. The parenchymal defect was closed with
horizontal interrupted sutures after sealant (Cyanoacrylate
glue, Tachosil, Floseal) and Tabotamp bolster apposition. Most
of the procedures were performed by one surgeon (M Carini,
61%).
After TE, the specimenswere oriented, positioning a suture
at the deepest part of the inner pole of the tumor, and sent for
histopathologic examination.2.2. Histopathology
After fixation in a 10% formalin solution, all specimens were
step-sectioned at 5-mm intervals, and the entire specimen
was analyzed by a dedicated uropathologist (C. di Cristofano).
The greatest diameters of the tumors were measured and
recorded. All patients were staged according to the 2002 TNM
criteria [24], and nuclear grading was assigned according to
criteria proposed by Fuhrman et al [25]. The histopathology
was reviewed according to the 2004 World Health Organiza-
tion (WHO) classification [26].
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determined as the mean value of the four fields evaluated
for each tumor. The existence, integrity, and degree of PS
invasion as well as d the thickness of the rim of normal-
appearing parenchyma, eventually present in case of tumor
beyond PS, were evaluated, capturing the images at 40 (3.0-
megapixel resolution), and analyzed using an image analyzer
(Motic Images Plus v.2.0).
Other variables assessed were tumor stage, histologic
subtype, Fuhrman grade, histologic necrosis, and sarcomatoid
differentiation.
2.3. Statistical analysis
The unpaired student t test and x2 test were used to evaluate
the possible statistical correlation between the clinical and
pathologic variables and the risk of PS+. The risk of PS invasion
related to other clinical and pathologic (continuous and
categorical) variables was evaluated using the logistic regres-
sion model, and odds ratios and risk ratios were calculated.
Significant-difference level was considered to be p < 0.05.
3. Results
At diagnosis, 87 of the 104 tumors (84%) were
detected incidentally in asymptomatic patients
while 17 (16%) were associated with either micro-
scopic or frank hematuria with or without flank
pain. Overall, 95 patients were treated with elective
TE (91%) while 9 patients received TE for imperative
indications (9%).
All patients with histologically confirmed RCC
were eligible for the study (90/104, 86.5%), and the 14
who had NSS for histologically confirmed benign
tumors were excluded (13.5%). At CT scan before
surgery, the mean of the greatest dimensions of the
tumors was 3.2 cm (range: 0.8–10 cm; SD: 1.5 cm;
median: 3.0 cm; interquartile range [IQR]: 2.0–
4.1 cm) and at the pathologic examination the mean
was 3.1 cm (range: 0.5–12.5 cm; SD: 1.7 cm; median:
2.9 cm; IQR: 2.1–3.8 cm), respectively.
The pathologic analysis according to the 2002
TNM classification showed that 75.6% of tumors
were pT1a, 16.7% of tumors were pT1b, 2.2% of
tumors were pT2, 4.4% of tumors were pT3a, and
1.1% of tumors were pT3b. On the basis of Fuhrman
nuclear grading, 20% of tumors were G1, 65.6% of
tumors were G2, and 14.4% of tumors were G3. The
histopathologic evaluation according to the 2004
WHO classification revealed that 75.6% of tumors
were clear-cell RCC, 17.8% were papillary; 4.4% of
tumors were chromophobe; 1.1% of tumors were
mucinous tubular and spindle-cell carcinoma, and
1.1% of tumors were unclassified RCC.
The presence of sarcomatoid differentiation was
detected in three cases (mean: 10.5%; range: 1–20%).Histologic tumor necrosis was present in 55.5% of all
RCC tumors, and it was often found as microscopic
isolated foci. Histologic necrosis was 20% in 47
cases (mean: 4.1%; median: 3%; range: 1–20%), while
it was >20% in only three RCC tumors.
All 90 RCC tumors were surrounded by a
continuous, nonfenestrated, fibrous PS composed
of dense connective fibrous tissue. PS thickness
presented only mild variations in every single
tumor, and in some cases there were signs of
neoplastic penetration within its layers, with or
without invasion beyond it. The mean (range)
thickness of the tumor PS was 0.39 mm (0.048–
0.798 mm).
PS status was classified as follows: PS intact and
free from invasion (PS; Fig. 2A); PS with signs of
neoplastic infiltration within its layers, with or
without invasion beyond it (PS+). PS+ was further
divided into four categories:
 PS with signs of neoplastic infiltration on the
parenchymal kidney sidewith no invasion beyond
it (PSK+; Fig. 2B)
 PS with signs of neoplastic infiltration and inva-
sion beyond it on the parenchymal kidney side
(PSK++; Fig. 2C and 2D)
 PS with signs of neoplastic infiltration on the
perirenal adipose tissue side with no invasion
beyond it (PSF+; Fig. 2E)
 PS with signs of neoplastic infiltration and inva-
sion of the adipose tissue (pT3a) (PSF++; Fig. 2F).
The PS features are reported in Table 1; in 60 RCC
tumors (66.7%) the PS was intact and free from
invasion (PS; Fig. 2A) while in 30 tumors (33.3%)
therewere signs of infiltrationwithin its layers, with
or without invasion beyond it (PS+). Indeed, 26.6% of
tumors (24/90) had PS invasion on the parenchymal
side; of those, 11 tumors (12.2% overall; 11/24, 45.8%
of tumors with PS invasion) had PS penetration
(PSK+; Fig. 2B), and 13 tumors (14.4% overall; 13/24,
54.2% of tumors with PS invasion) had PS penetra-
tion and invasion beyond it (PSK++; Fig. 2C and 2D).
The remaining 6 of 90 patients (6.6%) had PS
penetration on the perirenal fat tissue side, and of
those 2 patients (2.2%) had PS penetration (PSF+;
Fig. 2E) and 4 (4.4%) had penetration and invasion
beyond it (PSF++; pT3a; Fig. 2F).
The presence of PS+ by clinical and histologic
tumor dimension, tumor stage, nuclear grade, RCC
subtype and the presence of histologic necrosis is
reported in Table 2. PS+ was significantly associated
with clinical and pathologic tumor size, the pre-
sence of histologic necrosis and nuclear grade, while
there was no statistically significant correlation
Fig. 2 – (A) Pseudocapsule (PS) intact and free from invasion (PSS); (B) PS with signs of neoplastic infiltration on the
parenchymal kidney sidewith no invasion beyond it (PSK+); (C, D) PSwith signs of neoplastic infiltration and invasion beyond
it on the parenchymal kidney side (PSK++); (E) PSwith signs of neoplastic infiltration on the perirenal adipose tissue sidewith
no invasion beyond it (PSF+); (F) PS with signs of neoplastic infiltration and invasion of the adipose tissue (pT3a) (PSF++).
Abbreviations: K, kidney; T, tumor; F, perirenal fat.
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and the histologic subtype (clear-cell vs papillary vs
chromophobe) (Table 2).
Using logistic regression analysis, the odds of
having a PS invasion increased significantlywith the
increase in clinical tumor size, as measured by CT.
The odds ratio for the association of PS invasionwith
clinical tumor size was 1.412 (95% CI, 1.03–2.018),indicating that each 1-cm increase in clinical tumor
size was associated with a 41% increase in the odds
of PS invasion.
The presence of PS+ was also significantly
associated with pathologic tumor dimensions. The
difference between mean (SD) pathologic tumor
size of tumors with (3.8  2.32 cm) and without
(2.8  1.27 cm) PS involvement was statistically
Table 2 – Distribution of pseudocapsule-positive (PS+) by
clinical and histologic tumor dimension (D), tumor stage
by 2002 TNM classification, nuclear grade, renal cell
carcinoma (RCC) subtype, and the presence of histologic
necrosis
Tumor features PS status
PS PS+ p value
Clinical (CT) D max ( SD) 3.0 (1.28) 3.7 (1.71) 0.045
Pathological D max ( SD) 2.8 (1.27) 3.8 (2.32) 0.0134
RCC subtype
Clear-cell 45 (66.2%) 23 (33.8%) NS (0.77)
Papillary 11 (68.8%) 5 (31.2%)
Chromofobe 2 (50%) 2 (50%)
TNM stage
pT1a 51 (75%) 17 (25%) NS (0.24)
pT1b 9 (60%) 6 (40%)
Histologic necrosis
Absent 31 (77.5%) 9 (22.5%) 0.0512
Present 29 (58%) 21 (42%)
Nuclear grade
G1 16 (88.9%) 2 (11.1%) 0.0132
G2 39 (66.1%) 20 (33.9%)
G3 5 (38.5%) 8 (61.5%)
PS, pseudocapsule; PS, pseudocapsule negative for RCC; PS+,
pseudocapsule positive for RCC; CT, computed tomography.
Table 1 – Pseudocapsule (PS) features of 90 renal-cell
carcinoma (RCC) tumors from patients who had tumor
enucleation (TE)
PS status Number of cases %
PS 60 66.7%
PS+ 30 33.3%
PSK+ 11 12.2% (11/90)
PSK++ 13 14.4% (13/90)
PSF+ 2 2.2% (2/90)
PSF++ 4 4.4% (4/90)
Total 90 100%
PS, pseudocapsule negative for RCC and free from invasion; PS+,
pseudocapsule positive for RCC, with signs of neoplastic
infiltration within its layers, with or without invasion beyond it;
PSK+, PS with signs of neoplastic infiltration on the parenchymal
kidney side with no invasion beyond it; PSK++, PS with signs of
neoplastic infiltration and invasion beyond it on the parenchymal
kidney side; PSF+, PS with signs of neoplastic infiltration on the
perirenal adipose tissue side with no invasion beyond it; PSF++, PS
with signs of neoplastic infiltration and invasion of the adipose
tissue (pT3a).
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odds ratio for the association of PS invasion with
pathologic tumor size was 1.406 (95% CI, 1.035–
1.910), indicating that each 1-cm increase in patho-
logic tumor size was associated with a 40% increase
in the odds of PS invasion.
The risk (R) and risk ratio (RR) of PS+ by clinical
and pathologic tumor size for every 1-cm RCC
increase is reported in Table 3.
A logistic regression analysis was also performed
to predict the independent contribution of the
significant pathologic variables (nuclear grade,
histologic necrosis, and pathologic tumor dimen-
sion) to variations of the dichotomous dependent
variable (PS status). The results are shown in Table 4.
Pathologic tumor dimension and Fuhrman nuclear
grade (G1 vs G3) confirmed their significant pre-Table 3 – Expected risk (R) and risk ratio (RR, Ri/RiS1) of pseudo
dimension (D) for every centimeter increase (D = i )
D (cm) Clinical (CT) D max P
R (%) RR R (%
1 21.1 – 19.
2 27.4 1.3 24.
3 34.8 1.27 31.
4 42.9 1.23 39.
5 51.5 1.2 47.
6 60.0 1.16 56.
7 67.9 1.13 64.
CT, computed tomography.dictive value for PS+. In particular, therewas an 8.46-
fold increase in the risk of having PS+ for G3 RCCs
versus G1 RCCs.
In all cases of PS+, the SMs were negative
independent of the degree of PS penetration,
because even if there was invasion beyond the PS,
neoplastic cells were separated from the SM by a
thin layer of normal tissue with signs of lympho-
plasmocytic inflammation. This happened in all 13
caseswith PSK++ (Fig. 2C and 2D). In these cases, the
mean thickness of the rim of chronic inflammatory
tissue was 1.05 mm (SD: 0.48; median: 1.10; range:
0.38–1.60 mm).capsule-positive (PS+) by clinical and pathological tumor
athological D max Pathological D max if
grade = 1 and necrosis
is absent
) RR R (%) RR
0 – 5.3 –
8 1.31 7.1 1.34
6 1.28 9.5 1.33
2 1.24 12.6 1.32
8 1.21 16.5 1.31
3 1.18 21.3 1.29
4 1.14 27.1 1.27
Table 4 – Logistic regression analysis for different pathological variables
Odds ratio p value 95% CI Risk ratio
Pathological D max 1.371 0.0520 0.997–1.885 –
Histologic necrosis 1.09 0.8819 0.362–3.266 1.08
Fuhrman nuclear grade
G1 vs G2 4.37 0.0863 0.810–23.524 3.86
G1 vs G3 12.14 0.0155 1.607–91.716 8.46
CI, confidence interval; D, tumor dimension.
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To avoid the risk of local recurrence, the excision of a
minimal and visible margin of normal-appearing
parenchyma around the tumor is considered the
standard surgical technique of NSS [2].
Nevertheless, whether or not to excise a rim of
healthy parenchyma, theoretically necessary to
avoid the risk of a positive SM and local recurrence,
is a matter of great controversy, and recent reports
concluded that the width of the resection margins
does not correlate with disease progression and that
if the tumor is completely excised, themargin size is
irrelevant, thus providing an intriguing insight into
the possibility of bluntly excising the tumor, such as
a TE [13,14]. Moreover, from a functional point of
view, a narrower excision margin in RCC tumors
would lead to additional parenchymal tissue pre-
servation, and a recent report by Huang et al showed
that the new onset of GFR of <60 ml/min and of
<45 ml/min per 1.73 m2 in patients with small RCC
tumors can occur also after standard partial
nephrectomy in 20% and 5% of cases at 3-yr
follow-up, respectively [27].
The technical feasibility and oncologic safety of
blunt TE of a renal neoplasm depends on the
presence of a continuous fibrous PS around the
tumor and on the possibility of obtaining negative
SMs confirmed at the pathologic examination. The
first studies on this topic were reported in the mid-
twentieth century. In 1948, Cahill evaluated >30
kidney specimens with clear-cell RCC and con-
cluded that, with rare exceptions, the capsule
surrounding the tumor was smooth and had no
evidence of rupture [28]. In 1949, Beare and
McDonald studied the renal capsule in RCC and
found PS invasion in 15% of cases [29]. Then, from
the early 1980s, concurrently with the renewed
interest in conservative surgery, many reports
evaluated PS and SM status either on an RN
specimen or on the sole tumor, but after an ex vivo
TE, to investigate the real need to remove a rim of
healthy tissue around the tumor. These studies
noted some degree of PS invasion with RCC,irrespective of tumor size and histologic subtype,
with a higher rate in larger and less-differentiated
tumors, and thus TEwas not recommended because
of the significant risk of incomplete excision,
although none histologically analyzed the tumor
removed during an in vivo TE [8–10]. Indeed, Rocca
Rossetti et al noted a continuous PS in 80% of tumors
of <7 cm in diameter; in larger tumors this fraction
was only 23.5% [8]. Moreover, the degree of tumor
differentiation correlated inversely with the risk of
PS invasion [8]. In 1984, Rosenthal, in an ex situ TE
study on 25 RN specimens, noted some degree of
invasion of the PS in all cases, irrespective of tumor
size and histologic subtype [8]. Moreover, PS inva-
sion reaching the surface of the enucleated tumor
was more frequent in large tumors (>6 cm) and less
differentiated tumors [8].
We confirm, in this contemporary consecutive
series of patientswhowere candidates for openNSS,
that the PS can be penetrated irrespective of tumor
size in those undergoing conservative surgery, with
a reported infiltration rate of 26.6% on the parench-
ymal side and 6.6%on the perinephric adipose tissue
side.
Our data confirm those published by Li et al, who
recently reported a 27% incidence of PS invasion in
82 kidneys in which RCC tumors of <4 cm were
removed by RN [11]. Moreover, our study shows that,
as the clinical size of RCC tumors, measured by CT
increases, there is a significantly greater probability
that the tumor has invaded the PS. Indeed, each 1-
cm increase in clinical tumor size was associated
with a 41% increase in the odds of PS invasion. The
same applied when pathologic tumor size was
analyzed; the odds of having a PS invasion increased
significantly as pathologic tumor size increased.
Moreover we showed that tumor dimension was an
independent predictor of PS+ and that the risk ratio
of PS+ increased as tumor size increased even in
smaller tumors and even in the low-risk group of
patients with G1 RCC and no necrosis (Table 3). This
is the reason why there was no statistically
significant correlation between the risk of PS+ and
tumor stage. Indeed the 4-cm cutoff cannot define
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difference in PS+ rate.
In the present series, the risk of PS invasion was
also statistically associated with nuclear grade and
histologic necrosis. Nuclear grade appears to be an
independent risk factor for PS invasion, with a 3.86-
fold increase in the risk of PS invasion for G2 versus
G1 RCC, and an 8.46-fold increase in the risk for G3
versus G1, while the presence of necrosis was not
significant in the logistic regression analysis.
In this study all patients had an in vivo TE by blunt
dissection, thus overcoming the historical bias of
serieswhich analyzed this topic using RN specimens
or series which correctly evaluated the sole tumor,
but after an ex vivo TE. Moreover, this study design
provided for the possibility of defining the real risk
of positive SM after TE. We observed that if there
was PS penetration and invasion beyond it, the
presence of a thin layer of parenchymal tissue
invariably allowed for negative SM, even if no efforts
were made to leave a rim of healthy kidney tissue
around the neoplasm. In these cases, the mean
thickness of the rim of parenchymal tissue was
1.05 mm (SD: 0.48 mm; median: 1.10 mm; range:
0.38–1.60 mm).
These prospective data explain the excellent
results of TE for treating pT1a and pT1b tumors,
similar to the results of enucleoresection and RN
previously reported in retrospective studies [17–23].
We have routinely performed TE at our institution
since the early 1980s, reporting excellent long-term,
progression-free, and cancer-specific survival rates
with a mean follow-up of the more recent publica-
tions ranging between 74mo and 88mo [20–22]. This
study represents the first pathologic evaluation of
the TE technique performed in vivo.
Naturally, the present study can be criticized for
the lack of follow-up. The patients in this study,
followed for >2 yr, will enable us to further and
prospectively confirm that TE is not associated with
any greater risk of local recurrence than the
standard NSS and to correlate the risk of local
recurrence with PS status. Another limitation is that
some of the less frequent histologic subtypes and a
pT2 stage were present in a very small number of
cases and therefore were excluded from the statis-
tical analysis.
5. Conclusions
The PS can be infiltrated with or without invasion
beyond it in patients undergoing conservative
surgery, and the risk of PS invasion is statistically
associated with clinical and pathologic tumordimensions and nuclear grade. If there is PS
penetration and invasion beyond it, the presence
of a thin layer of parenchymal tissue allows for
negative SM even if no efforts are made to leave a
rim of healthy kidney tissue around the neoplasm.
Our data clearly represent a rationale for adopting
the TE technique as the standard procedure for the
excision of pT1a and pT1b RCC tumors.
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